Yes, Keynote 200 (Cavatak/Keytruda) includes a study with non small cell lung cancer. Lots of other companies are running Phase 3 trials with a chemo/PD1 combos. We need to get in there too!
VLA Price at posting:
72.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
